Contrary to the data of Bedrosian et al, reporting this rate as 18.8%, the lower rate of nodal involvement after systemic therapy merits consideration, particularly in the era of precision medicine, leading higher than 80% of pathologic complete response rates after NST for selected patients with triple negative or HER-2 positive breast cancer under dual agent blockage.[27] In the presented series, 67.3% of the cases were HER-2 positive and had dual agent blockage in the neoadjuvant setting. The gene discussed is ERBB2; the disease is breast carcinoma.